The significant decrease in the plasma concentration of MMP13 between the control group and the neovascular AMD group suggests a difference in the profile of cells releasing this metalloproteinase circulating in blood or residing in the parenchyma of other tissues, or the existence of other molecules, including other MMPs, that counteract the overexpression observed in the eye. Here, MMP13 is linked to age-related macular degeneration.